Back HIV/AIDS

HIV / AIDS

IAS 2015: Targets Proliferate in HIV Cure Research

The Towards an HIV Cure two-day symposium has become a fixture in advance of the International AIDS Society conferences and the meeting last week in Vancouver featured a more varied range of experimental approaches than ever in the search for ways of eliminating HIV infection from the body.

alt

White House Releases Updated National HIV/AIDS Strategy

On July 30 the White House released an updated version of its National HIV/AIDS Strategy, outlining the administration's plans through the year 2020. In keeping with recent research, the revised strategy includes an increased emphasis on early antiretroviral treatment and pre-exposure prophylaxis (PrEP), as well as focusing on underserved and heavily affected population groups including young gay men, transgender women, and African-Americans.

alt

IAS 2015: Long-term HIV Remission [VIDEO]

A French teenager with HIV who has maintained an undetectable viral load for 12 years while off antiretroviral treatment was among the most widely discussed topics at the 8th International AIDS Society Conference last week in Vancouver. While no one is calling this case a cure, it does raise interesting questions about "post-treatment control" and may provide clues about how to achieve a functional cure or long-term HIV remission.

alt

IAS 2015: Vancouver's HIV Treatment as Prevention Success Also Due to Harm Reduction

"We talk a lot about the success of treatment as prevention in Vancouver, but we always need to make sure people understand that this requires an integration of various approaches," Evan Wood of the University of British Columbia said last week in a plenary presentation at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.

alt

IAS 2015: The Health Economics of HIV Treatment [VIDEO]

The world faces an opportunity to expand antiretroviral therapy to all who need it -- both to improve the health of individuals living with HIV and to prevent transmission of the virus -- and treatment would likely be cost-effective, experts agreed at a press briefing at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention last week in Vancouver.

alt

IAS 2015: Gay Youth PrEP Study Finds Good Retention and Reasonable Adherence

A U.S. study of Truvada pre-exposure prophylaxis (PrEP) looking at 200 young gay and bisexual men aged 18-22 in a dozen cities found reasonable levels of adherence, researchers reported at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last week in Vancouver. Adherence was highest among those with the highest risk of HIV. However, adherence dropped off considerably after study visits changed from monthly to quarterly, suggesting that gay youth starting PrEP would benefit from more intensive support than older participants. The study also found considerably lower adherence among young black and mixed-race men.

alt

IAS 2015: U.S. PrEP Demo Project Finds People at Highest HIV Risk Take PrEP Most Consistently

An open-label demonstration project of Truvada pre-exposure prophylaxis (PrEP) in the U.S. has found generally high retention and adherence rates, with the highest adherence among people at the highest risk of HIV infection, researchers reported at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) last week in Vancouver. However, some groups appeared to have more difficulty taking PrEP -- most notably young people and black people, and it proved difficult to recruit black men and transgender women -- to the project.

alt